Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01159028 |
Recruitment Status
:
Active, not recruiting
First Posted
: July 9, 2010
Last Update Posted
: January 18, 2018
|
Sponsor:
Bio-Path Holdings, Inc.
Information provided by (Responsible Party):
Bio-Path Holdings, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | December 31, 2019 |
Estimated Study Completion Date : | December 31, 2019 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):